Physician profile
Amy Pullizzi
NPI 1619383502
$1,441.10
in general payments reported to CMS, 2019-2025
20 companies · $145 in 2025
The $145 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $343 · 2023: $432 · 2024: $521 · 2025: $145.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,072 · Education: $26.73.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,071.62 |
| Education | $26.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $207.29 | 2024 | |
| Abbvie INC. | $175.44 | 2022-2025 | |
| Alnylam Pharmaceuticals INC. | $143.99 | 2023 | Amvuttra |
| Abbott Laboratories | $139.89 | 2023 | Thoratec Heartmate 3 Lvas Implant Kit |
| Shield Therapeutics INC | $115.31 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $104.76 | 2024 | |
| Novo Nordisk INC | $103.43 | 2022 | |
| Amylyx Pharmaceuticals, INC. | $102.20 | 2023 | Relyvrio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.69 | 2023-2025 | Spevigo |
| Grifols USA, LLC | $43.08 | 2024 | Gamunex-C, Prolastin-C Liquid |
| Glaxosmithkline, LLC. | $34.15 | 2024 | Nucala |
| Csl Behring | $32.42 | 2024 | Privigen |
| Lundbeck LLC | $31.76 | 2024 | Vyepti |
| Astrazeneca Pharmaceuticals LP | $27.91 | 2024 | Fasenra |
| Genentech USA, INC. | $24.47 | 2023 | Ocrevus |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $24.05 | 2025 | Cabenuva |
| Biogen, INC. | $23.47 | 2024 | Leqembi |
| Ucb, INC. | $22.96 | 2025 | Rystiggo |
| Argenx US, INC. | $18.72 | 2025 | Vyvgart Hytrulo |
| Takeda Pharmaceuticals U.S.A., INC. | $16.11 | 2024 | Entyvio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Pullizzi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.